- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07943312
GA001 Injection in Retinitis Pigmentosa
A Clinical Study to Evaluate the Safety and Efficacy of GA001 Injection in Patients With Retinitis Pigmentosa
This Phase II clinical trial evaluates the safety, tolerability, and efficacy of GA001 Injection in patients with retinitis pigmentosa.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Retinitis pigmentosa (RP) is an inherited retinal disease that causes gradual vision loss and can lead to blindness, with no approved curative treatment currently available.
This Phase II study is designed to evaluate the safety, tolerability, and efficacy of a single unilateral intravitreal injection of GA001 Injection at the target dose compared with sham injection in patients with retinitis pigmentosa. The study employs a sham-controlled design and will assess safety and efficacy outcomes as well as multiple functional and structural measures of visual performance over long-term follow-up.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Xiaodong Sun Principal Investigator, PhD
- Telefoonnummer: 86 17853138155
- E-mail: xdsun@sjtu.edu.cn
Studie Locaties
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200080
- Shanghai General Hospital
-
Contact:
- Xiaodong Sun
- Telefoonnummer: 86-1566269037
- E-mail: guanranzhang@126.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Male or female participants aged 18 to 70 years.
- Clinical diagnosis of advanced retinitis pigmentosa (RP).
- Best corrected visual acuity at or below the protocol-defined threshold in the study eye.
- Ability to understand and sign informed consent (and assent, when applicable).
- Laboratory test results are within the protocol-defined threshold range.
Exclusion Criteria:
- Presence of other ocular conditions that could interfere with study assessments.
- History of significant ocular surgery in the study eye within a protocol-defined period.
- Active ocular infection or inflammation.
- Clinically significant systemic disease that could increase study risk or interfere with assessments.
- Positive screening for clinically significant infectious diseases, as defined in the protocol.
- Any condition that, in the investigator's judgment, would make the participant unsuitable for study participation.
- Pregnant or breastfeeding individuals.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: GA001
|
Single unilateral IVT injection of GA001 Injection in the study eye |
|
Sham-vergelijker: Sham Injection
|
Sham IVT procedure in the study eye |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
To evaluate the efficacy of GA001 Injection in patients with retinitis pigmentosa
Tijdsspanne: Baseline to Week 52
|
BCVA-Change from Baseline in LogMAR Best Corrected Visual Acuity (BCVA) BCVA assessed by ETDRS charts at each post-treatment visit compared with the sham group.baseline→W52,Unit: LogMAR MLMT-Change from Baseline in Multi-Luminance Mobility Test (MLMT) Performance MLMT 7 levels; baseline→W52 ambient Lux to finish course, vs. sham. Unit: Lux Light Sensitivity-Change from Baseline in Light Sensitivity (Minimum Identifiable Brightness) Min brightness (Lux), study eye; baseline→W52, vs. sham. Unit: Lux FST Threshold-Change from Baseline in Full-Field Stimulus Test (FST) Threshold Full-field stimulus test; baseline→W52, vs. sham. Unit: log cd·s/m² Central Visual Field-Change from Baseline in Central Visual Field Static perimetry; baseline→W52, vs. sham. Unit: dB (mean deviation) MRDQ-Change from Baseline in Michigan Retinal Degeneration Questionnaire (MRDQ) Total Score MRDQ total score; baseline→W52, vs. sham. Unit: total score (points) |
Baseline to Week 52
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events and serious adverse events
Tijdsspanne: Baseline to Week 52
|
Incidence of severity of ocular and systemic adverse events (AEs) and serious adverse events (SAEs) following a single intravitreal injection of GA001 |
Baseline to Week 52
|
|
Evaluation of the Immunogenicity of GA001 Injection after a Single Intravitreal Administration in Patients with Retinitis Pigmentosa
Tijdsspanne: Baseline to Week 52
|
Immunogenicity of GA001 Injection will be evaluated following a single intravitreal injection in patients with retinitis pigmentosa, by AAV neutralizing antibody titers in peripheral blood (cell-based neutralizing assay) and by analysis of GA001-specific T-cell immune responses. |
Baseline to Week 52
|
|
Maximum Concentration (Cmax) of GA001 Vector DNA
Tijdsspanne: Baseline to Week 52
|
Cmax of GA001 vector DNA will be determined by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa. |
Baseline to Week 52
|
|
Area Under the Concentration-Time Curve (AUC) of GA001 Vector DNA
Tijdsspanne: Baseline to Week 52
|
AUC of GA001 vector DNA will be determined by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa. |
Baseline to Week 52
|
|
Time to Maximum Concentration (Tmax) of GA001 Vector DNA
Tijdsspanne: Baseline to Week 52
|
Tmax of GA001 vector DNA will be determined by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa. |
Baseline to Week 52
|
|
Biodistribution of GA001 Vector DNA
Tijdsspanne: Baseline to Week 52
|
Biodistribution of GA001 vector DNA will be assessed by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa. |
Baseline to Week 52
|
|
Shedding of GA001 Vector DNA
Tijdsspanne: Baseline to Week 52
|
Shedding of GA001 vector DNA will be assessed by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa. |
Baseline to Week 52
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- GA001-2025
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .